HOOKIPA PHARMA INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 39 rows in 2019. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2019-12-19: Reporting owner Matushansky Igor; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2019-12-19: Reporting owner Matushansky Igor; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2019-12-18: Reporting owner van de Winkel Jan; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2019-12-18: Reporting owner Lengauer Christoph; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2019-12-19 | Matushansky Igor Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | +6,000 40,375 owned after | $0.10 | 2019-12-23 | |
| 2019-12-19 | Matushansky Igor Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | +19,891 25,575 owned after | $0.10 | 2019-12-23 | |
| 2019-12-18 | van de Winkel Jan Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +28,800 28,800 owned after | $9.96 exercise price | 2020-01-03 | |
| 2019-12-18 | Lengauer Christoph Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,600 9,600 owned after | $9.96 exercise price | 2020-01-03 | |
| 2019-12-18 | O'Neill Julie Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,600 9,600 owned after | $9.96 exercise price | 2020-01-03 | |
| 2019-12-18 | Seghezzi Graziano Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,600 9,600 owned after | $9.96 exercise price | 2020-01-03 | |
| 2019-12-18 | van Deventer Sander Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,600 9,600 owned after | $9.96 exercise price | 2020-01-03 | |
| 2019-12-17 | Matushansky Igor Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | +26,312 46,375 owned after | $0.10 | 2019-12-19 | |
| 2019-12-09 | Necina Roman Officer (Chief Technology Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +125,008 125,008 owned after | $8.21 exercise price | 2019-12-11 | |
| 2019-04-17 | Matushansky Igor Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +52,064 52,064 owned after | $14.00 exercise price | 2019-04-24 | |
| 2019-04-17 | Pinschewer David Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +116,416 116,416 owned after | $14.00 exercise price | 2019-04-24 | |
| 2019-04-17 | Lengauer Christoph Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,924 6,924 owned after | $14.00 exercise price | 2019-04-24 | |
| 2019-04-17 | Kandera Reinhard Director, Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +87,648 87,648 owned after | $14.00 exercise price | 2019-04-24 | |
| 2019-04-17 | O'Neill Julie Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,924 6,924 owned after | $14.00 exercise price | 2019-04-24 | |
| 2019-04-17 | Orlinger Klaus Officer (Sr. VP, Research) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +42,784 42,784 owned after | $14.00 exercise price | 2019-04-24 | |
| 2019-04-17 | Kelly Michael Aaron Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +19,200 19,200 owned after | $14.00 exercise price | 2019-04-24 | |
| 2019-04-17 | Kaufman David Ross Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −19,200 19,200 owned after | $14.00 exercise price | 2019-04-24 | |
| 2019-04-17 | Aldag Jorn Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +604,656 604,656 owned after | $14.00 exercise price | 2019-04-24 | |
| 2019-04-17 | Seghezzi Graziano Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +19,200 19,200 owned after | $14.00 exercise price | 2019-04-24 | |
| 2019-04-17 | Lilja Anders Officer (Sr. VP, Technical Development) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +42,784 42,784 owned after | $14.00 exercise price | 2019-04-24 | |
| 2019-04-17 | van Deventer Sander Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +19,200 19,200 owned after | $14.00 exercise price | 2019-04-24 | |
| 2019-04-17 holding as of filing | Aldag Jorn Director, Officer (Chief Executive Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.10 exercise price | 2019-04-17 | ||
| 2019-04-17 holding as of filing | Matushansky Igor Officer (Chief Medical Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.10 exercise price | 2019-04-17 | ||
| 2019-04-17 holding as of filing | Matushansky Igor Officer (Chief Medical Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.10 exercise price | 2019-04-17 | ||
| 2019-04-17 holding as of filing | Matushansky Igor Officer (Chief Medical Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.10 exercise price | 2019-04-17 | ||
| 2019-04-17 holding as of filing | Matushansky Igor Officer (Chief Medical Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $10.33 exercise price | 2019-04-17 | ||
| 2019-04-17 holding as of filing | Kandera Reinhard Director, Officer (Chief Financial Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.10 exercise price | 2019-04-17 | ||
| 2019-04-17 holding as of filing | Kandera Reinhard Director, Officer (Chief Financial Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.10 exercise price | 2019-04-17 | ||
| 2019-04-17 holding as of filing | Lilja Anders Officer (Sr. VP, Technical Development) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.10 exercise price | 2019-04-17 | ||
| 2019-04-17 holding as of filing | Lilja Anders Officer (Sr. VP, Technical Development) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.10 exercise price | 2019-04-17 | ||
| 2019-04-17 holding as of filing | Lilja Anders Officer (Sr. VP, Technical Development) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.10 exercise price | 2019-04-17 | ||
| 2019-04-17 holding as of filing | O'Neill Julie Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $10.33 exercise price | 2019-04-17 | ||
| 2019-04-17 holding as of filing | Orlinger Klaus Officer (Sr. VP, Research) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.10 exercise price | 2019-04-17 | ||
| 2019-04-17 holding as of filing | Orlinger Klaus Officer (Sr. VP, Research) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.10 exercise price | 2019-04-17 | ||
| 2019-04-17 holding as of filing | Orlinger Klaus Officer (Sr. VP, Research) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.10 exercise price | 2019-04-17 | ||
| 2019-04-17 holding as of filing | Orlinger Klaus Officer (Sr. VP, Research) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.10 exercise price | 2019-04-17 | ||
| 2019-04-17 holding as of filing | van de Winkel Jan Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.10 exercise price | 2019-04-17 | ||
| 2019-04-17 holding as of filing | Lengauer Christoph Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $10.33 exercise price | 2019-04-17 | ||
| 2019-04-17 holding as of filing | Pinschewer David Officer (Chief Scientific Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.10 exercise price | 2019-04-17 |